Even though receptor-/ligand-specific antibodies can target NF-κB signaling with high specificity, the diverse NF-κB signals in MM cells and their microenvironment limit the application of these therapies to treat MM effectively in vivo. Here, NFKB1 is linked to Miyoshi myopathy.